Development of Neuritin 1 as a Therapeutic Candidate for Obesity and Metabolic Liver Disease

Obesity and related diseases, such as Metabolic Dysfunction-Associated Steatotic Liver Disease, are a major global health crisis and are closely associated with cardiovascular risk. Current treatments are not sufficient, and we urgently need new drugs. This research focuses on a protein called Neuritin 1 (NRN1), which is a key regulator of brown fat metabolism. Brown fat burns calories, increasing energy use and reducing body fat. Our initial studies found that NRN1 reduces fat in mice fed a high-fat diet, showing its potential as a drug.

The NEURIMET project will test these findings in humans and seek to understand exactly how NRN1 works. It is expected to develop a superior variant of NRN1 into a powerful treatment for human metabolic disorders.

NEURIMET is funded by La Caixa Foundation. The project is carried out by the groups of Juan B. Blanco  (IQAC), José M. Fernández Real (Institut D’Investigació Biomèdica de Girona), and Antonio Zorzano (IRB Barcelona, leading group).

Project information

Current

Acronym

NEURIMET

Start

01/10/2026

End

30/09/2029

Project call

Health Research 2026

Project reference

HR26-00218

Coordinated by IQAC

No

Innovation action

Yes

Total budget

999.111 €

IQAC budget

296.020 €

Principal investigator

Juan Bautista Blanco

Research Scientist

Other staff involved